ライフサイエンスコーパス: ocular surface

1 secretion of the protective GC mucins on the ocular surface.

2 etion, and the loss of dendriform DCs at the ocular surface.

3 CFTR) is a major prosecretory channel at the ocular surface.

4 have applicability to other diseases of the ocular surface.

5 oride (BAK), which can negatively affect the ocular surface.

6 film, that helps to nourish and protect the ocular surface.

7 ce secretions that lubricate and protect the ocular surface.

8 n aerosol inoculum exclusively to the ferret ocular surface.

9 actors are known to affect the health of the ocular surface.

10 ting inflammatory conditions of the anterior ocular surface.

11 y innervated to sustain the integrity of the ocular surface.

12 nd infiltration of inflammatory cells to the ocular surface.

13 tory factors in promoting homeostasis at the ocular surface.

14 um is altered, with a negative impact on the ocular surface.

15 o produce enough tears to maintain a healthy ocular surface.

16 ree-dimensional (3D) coculture model for the ocular surface.

17 bular organ that protects and lubricates the ocular surface.

18 in 30.9% (51/165 eyes) to maintain a stable ocular surface.

19 maintenance of the epithelial barrier at the ocular surface.

20 a major prosecretory chloride channel at the ocular surface.

21 s occurring by instilling an allergen on the ocular surface.

22 eptor (NK1R), are reported to present on the ocular surface.

23 r characterized by an abnormal tear film and ocular surface.

24 ich play an important role in protecting the ocular surface.

25 to rapid clearance (low residence time) from ocular surface.

26 sed areas of the skin, mucous membranes, and ocular surfaces.

27 atients in category 2 had significantly more ocular surface abnormalities than patients in category 1

28 capacity of licensed vaccines to protect the ocular surface against infection is limited.

29 Sixty-four VDT workers were screened for ocular surface alterations using OSDI and tear osmolarit

30 OSDI, when screening VDT users for possible ocular surface alterations.

31 while 15.2% (25/165) maintained an improved ocular surface and 12.1% (20/165) developed total surfac

32 ns and symptoms of acute inflammation of the ocular surface and adnexa was evaluated in 411 subjects.

33 eatment period was able to restore a healthy ocular surface and corneal barrier function with compara

34 Mild ocular surface and corneal disease may be treated effect

35 rocedure has a less pronounced impact on the ocular surface and corneal innervation compared with LAS

36 n; however, these medications may affect the ocular surface and elicit ocular discomfort when preserv

37 Initial correlation between OSA and ocular surface and eyelid markers was calculated through

38 cuity, dry eye severity, and scarring of the ocular surface and eyelids were assessed after follow-up

39 resident commensal microbiome exists on the ocular surface and identify the cellular mechanisms unde

40 ents include the ability to treat the entire ocular surface and prevention of surgical complications.

41 FPR2 receptor to maintain homeostasis of the ocular surface and regulate histamine responses and coul

42 Severity of ocular surface and systemic disease was graded.

43 complex 3D model as a recapitulation of the ocular surface and tear film system, which can be furthe

44 oving surfaces, such as articulating joints, ocular surfaces and the lungs.

45 Lubricant ointment use, a compromised ocular surface, and bandage contact lens use are associa

46 cant ointment use, presence of a compromised ocular surface, and bandage contact lens use were associ

47 Our findings help explain some of the ocular surface anomalies seen in children with EB.

48 arly inducible gene 1, also increased at the ocular surface at both the protein and gene levels.

49 7 cells are critical effectors mediating the ocular surface autoimmunity in dry eye disease (DED).

50 clearly demonstrate that Th17 cells mediate ocular surface autoimmunity through both IL-17A and IFN-

51 tudy was undertaken to evaluate the external ocular surface bacterial isolates and their antimicrobia

52 teolytic cleavage may contribute to impaired ocular surface barrier function.

53 es) limbal stem cell deficiency secondary to ocular surface burns (2 eyes), trauma (1 eye) and conjun

54 and vision restoration in unilateral chronic ocular surface burns.

55 port the safety of predatory bacteria on the ocular surface, but future studies are warranted regardi

56 ntive and measurable impacts not only on the ocular surface, but on quality of life and visual functi

57 Ocular surface cancer or a history of ocular surface can

58 Ocular surface cancer or a history of ocular surface cancer was present in 10% of patients.

59 treatment for periocular cancers and 2% for ocular surface cancers.

60 ttle is known about the toxicity of SiNPs on ocular surface cells such as human corneal epithelial ce

61 d overproduced Th2 cytokine were observed in ocular surface, cervical lymph nodes and isolated CD4(+)

62 Allgrove's 4A syndrome determines ocular surface changes.

63 and management of VKC and other inflammatory ocular surface conditions.

64 C function resulted in MG disease and severe ocular surface damage that phenocopied aspects of human

65 rz/brim/tim were well tolerated with minimal ocular surface damage.

66 Neutralization of NKG2D at the ocular surface decreased the expression of CXCL9, CXCL10

67 crobial keratitis on bacterial adaptation to ocular surface defenses, combined with changes to the bi

68 inflammatory activity rapidly, triggering an ocular surface deterioration.

69 ure research regarding the mechanisms behind ocular surface discomfort in patients with tear film dis

70 lated subscore (derived from questions about ocular surface discomfort) were calculated for each subj

71 eusis in situ (2 eyes), and undifferentiated ocular surface disease (4 eyes).

72 , yeasts were the predominant isolates, with ocular surface disease (OSD) being the leading risk fact

73 The purpose of our study was to compare Ocular Surface Disease (OSD) signs and symptoms of Taflu

74 halmologists treating glaucoma patients with ocular surface disease (OSD).

75 drainage device (P = .023), and preexisting ocular surface disease (P = .037) were associated with r

76 OOKP procedures were performed for severe ocular surface disease according to the indications and

77 Many of these syndromes can lead to ocular surface disease and are becoming more prevalent a

78 ew and update on recent literature regarding ocular surface disease and corneal refractive surgery.

79 ing body of research that links androgens to ocular surface disease and DED.

80 Ocular surface disease and its complications were associ

81 Rapid blinking is associated with worse ocular surface disease and tear stability.

82 Studies involving ocular surface disease and/or keratorefractive (corneal)

83 r scleral lens therapy for the management of ocular surface disease between June 1, 2006, and Novembe

84 es, such as Meckel syndrome, present several ocular surface disease conditions of unclear pathogenesi

85 Ocular surface disease due to an autoimmune cause demons

86 tative markers of eyelid laxity or secondary ocular surface disease in a sleep clinic population.

87 y is a validated questionnaire that assesses ocular surface disease in the context of vision-related

88 trols, at baseline, included mean scores for Ocular Surface Disease Index (31.7 vs 4.1, P < 0.0001),

89 ation including symptom assessment using the Ocular Surface Disease Index (OSDI) and corneal fluoresc

90 al microscopy (IVCM) and were surveyed using Ocular Surface Disease Index (OSDI) and Glaucoma Symptom

91 ptoms of ocular GVHD were assessed using the Ocular Surface Disease Index (OSDI) and Symptom Assessme

92 Ocular Surface Disease Index (OSDI) questionnaire scores

93 mic assessment including a detailed history, Ocular Surface Disease Index (OSDI) questionnaire, and o

94 Patient symptoms were assessed using the Ocular Surface Disease Index (OSDI) questionnaire.

95 howed 3 of the following 4 dry eye criteria: ocular surface disease index (OSDI) score of more than 1

96 after PROSE fitting using Snellen acuity and Ocular Surface Disease Index (OSDI) survey.

97 Outcome variables were the Ocular Surface Disease Index (OSDI) symptom questionnair

98 al Function Questionnaire (NEI-VFQ), and the Ocular Surface Disease Index (OSDI) were included.

99 of dry eye disease (DED) as assessed by the Ocular Surface Disease Index (OSDI), a 12-item symptom f

100 c tests for dry eye disease (DED), including ocular surface disease index (OSDI), tear breakup time (

101 Symptoms were evaluated using the Ocular Surface Disease Index (OSDI).

102 isual-related function subscale score of the Ocular Surface Disease Index (VR-OSDI).

103 in (1) tear osmolarity and (2) DED symptoms (Ocular Surface Disease Index [OSDI] score) between days

104 ich included vision-related quality of life (Ocular Surface Disease Index [OSDI]), clinical examinati

105 Dry eye symptoms (Ocular Surface Disease Index [OSDI]), signs (tear break-

106 taining scores [Ora scales]) and subjective (Ocular Surface Disease Index [OSDI], 7-item visual analo

107 mptoms (5-Item Dry Eye Questionnaire [DEQ5], Ocular Surface Disease Index [OSDI], and Neuropathic Pai

108 onjunctival staining, meibomian grading, and Ocular Surface Disease Index and SF-36v2 questionnaires

109 articipants in the PROWL-2 study with normal Ocular Surface Disease Index scores were 44% (95% CI, 38

110 articipants in the PROWL-1 study with normal Ocular Surface Disease Index scores were 55% (95% CI, 48

111 Satisfaction with Correction subscales; the Ocular Surface Disease Index's (OSDI's) Symptoms subscal

112 Primary endpoints were mean IOP change and Ocular Surface Disease Index(c) (OSDI) score at each vis

113 tear osmolarity (TearLab system), symptoms (Ocular Surface Disease Index), and corneal fluorescein s

114 ng, and an irritation symptom questionnaire (Ocular Surface Disease Index).

115 or a clinical diagnosis of dry eye using the Ocular Surface Disease Index, Schirmer tear test, tear b

116 y where the residents were studied using the Ocular Surface Disease Index, together with diagnostic t

117 Ocular surface disease is an important risk factor for g

118 festations noted were hyperopia and signs of ocular surface disease owing to nocturnal lagophthalmos

119 y of Life 17 (Glau-QoL17) questionnaire, and Ocular Surface Disease Quality of Life (OSD-QoL) questio

120 In a large cohort of patients with chronic ocular surface disease related to SJS/TEN, PROSE treatme

121 Here, we used a mouse model of ocular surface disease to reveal that commensals were pr

122 h DALK (P = .03) and PKP (P = .002), whereas ocular surface disease was a significant risk factor for

123 Ocular surface disease was significantly more common in

124 Eyelid laxity and ocular surface disease were assessed on bedside ophthalm

125 Dry eye is a complicated ocular surface disease whose exact pathogenesis is not y

126 To treat ocular surface disease with a topical biotherapeutic, th

127 d with greater irritation, tear instability, ocular surface disease, and blink rate.

128 hthalmos is an often-overlooked component of ocular surface disease, and its prevalence is likely on

129 -negative ulcers, viral etiology, coexistent ocular surface disease, and multiple grafts were exclude

130 ast hope for restoration of vision in severe ocular surface disease, and the retinal surgeon is frequ

131 VR)-induced skin pigmentation, skin cancers, ocular surface disease, and, in some patients, sunburn a

132 ta-thalassemia ocular manifestations include ocular surface disease, as demonstrated by tear function

133 r scleral lens therapy were undifferentiated ocular surface disease, exposure keratopathy, and neurot

134 r graft failure (corneal neovascularization, ocular surface disease, glaucoma, active corneal inflamm

135 ective device for rehabilitation in advanced ocular surface disease, resulting in a significant impro

136 developed treatment for patients with severe ocular surface disease.

137 of scleral lens therapy in the management of ocular surface disease.

138 used in the management of moderate to severe ocular surface disease.

139 ropriate treatment, and better management of ocular surface disease.

140 or serious ophthalmic complications owing to ocular surface disease.

141 bsent ENaC function in the MG and associated ocular surface disease.

142 91 among patients with end-stage corneal and ocular surface diseases at an additional cost of S$67 84

143 biotechnology-based treatment agent against ocular surface diseases where endogenous lacritin is ina

144 discuss recent advances in MSC for treating ocular surface diseases.

145 ment for patients with end-stage corneal and ocular surface diseases.

146 accine and therapeutic development for other ocular surface diseases.

147 elia are central in the pathogenesis of many ocular surface disorders.

148 ntity that can cause evaporative dry eye and ocular surface disruption, leading to dry eye symptoms i

149 UT and blink rate and greater irritation and ocular surface dye staining with 1 or both esthesiometer

150 a direct correlation with corneal stain and ocular surface dysfunction and an inverse correlation fo

151 ng these parameters was considered a sign of ocular surface dysfunction.

152 the impact of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment on visual acu

153 zones is indicative of lineage, spanning the ocular surface ectoderm, lens, neuro-retina, and retinal

154 ics, resembling neuroectoderm, neural crest, ocular-surface ectoderm, or surface ectoderm.

155 es, including retinal cells, lens cells, and ocular-surface ectoderm.

156 te this we show that cells isolated from the ocular surface ectodermal zone of the SEAM can be sorted

157 on clinical and experimental literature for ocular surface effects of glaucoma therapy and to provid

158 The ocular surface epithelia, including the stratified but n

159 mined by the direct autoimmune insult to the ocular surface epithelia, whereas in MGD patients, with

160 is transcribed, translated, and expressed by ocular surface epithelia.

161 l of the SEAM, cells within it that resemble ocular-surface epithelia can be isolated by pipetting an

162 tis, interleukin-1beta (P = 0.025), in their ocular surface epithelial cells compared with homozygous

163 pression of the encoded glycoprotein TSP1 in ocular surface epithelial cells significantly increases

164 s, lead to an inflammatory cycle that causes ocular surface epithelial disease and neural stimulation

165 atin 14-positive stratified epithelia causes ocular surface epithelial hyperplasia and conjunctival g

166 ection improved the RNA yield of the in situ ocular surface epithelial regions for effective microarr

167 ve the desired RNA concentration the area of ocular surface epithelial tissue sample processed for th

168 n activates stress signaling pathways in the ocular surface epithelium and resident immune cells.

169 Expression of ICAM-1 by ocular surface epithelium decreased significantly in bot

170 in the absence of an external phenotype, the ocular surface epithelium develops properly, but young m

171 Fgfr2 deletion in the ocular surface epithelium reduced Sox9 and eliminated So

172 sporadically expressed in the basal cells of ocular-surface epithelium.

173 eye by combining in vivo PAM imaging and an ocular surface estimation method based on a machine lear

174 Patients had their ocular surface evaluated with slit-lamp biomicroscopy, a

175 ity with tear MUC5AC concentration and other ocular surface evaluation factors.

176 our knowledge, this is the first prospective ocular surface evaluation in children with EB to include

177 e and smoking questionnaires, in addition to ocular surface evaluation.

178 status, and medication use and underwent an ocular surface examination.

179 face Disease Index (OSDI) questionnaire, and ocular surface examination.

180 ificantly increases antibiotic resistance of ocular surface flora.

181 n developed that can release the drug on the ocular surface for a longer duration of time than drops,

182 and respiratory tracts, but its function in ocular surface has yet to be fully characterized.

183 d new technologies to evaluate the tears and ocular surface have improved the ability to diagnose, cl

184 It seems reasonable to optimize ocular surface health and to delay PK.

185 =50% improvement of symptoms, improvement in ocular-surface health, reduction in artificial tear use,

186 Recently, we showed an altered ocular surface homeostasis in unmanipulated NK1R(-/-) mi

187 suggesting the role of SP-NK1R signaling in ocular surface homeostasis under steady-state.

188 fibrosis while alluding to broader roles in ocular surface immunity and allogenic organ transplantat

189 TOPIC: To discuss the pathology, causes, and ocular surface impact of meibomian gland disease (MGD),

190 terms of pathophysiology, risk factors, and ocular surface impact, and the relationship to dry eye.

191 that even PF formulations may lead to a mild ocular surface impairment.

192 tem cell transplantation, there was a stable ocular surface in 12 of 14 eyes (86%) and improvement in

193 ort providing an up-to-dated analysis of the ocular surface in an affected patient.

194 entional MT in maintaining BCVA and a stable ocular surface in cases of acute ocular SJS.

195 late Cl(-)-driven fluid secretion across the ocular surface in mice.

196 TLR agonist cocktail was applied to the ocular surface in untreated (UT), corneal scratched, and

197 bnormalities were in the periocular skin and ocular surface, including interpalpebral conjunctival me

198 Pterygium is a disorder of the ocular surface induced by chronic exposure to UV-light.

199 pidemic keratoconjunctivitis (EKC), a severe ocular surface infection.

200 and epidemic keratoconjunctivitis, a severe ocular surface infection.

201 reases the susceptibility to develop chronic ocular surface inflammation after refractive surgery.

202 especially helpful to identify patients with ocular surface inflammation and autoimmune disease and m

203 dry eye tests and identified the presence of ocular surface inflammation in 40% of confirmed dry eye

204 ural component of blueberries, in preventing ocular surface inflammation using an in vitro culture mo

205 Ocular surface inflammation was common during the acute

206 Fourteen patients (56%) presented with ocular surface inflammation.

207 40% of SJS and 75% of TEN patients had acute ocular surface inflammation.

208 se changes were accompanied by a decrease in ocular surface inflammatory cytokine levels and corneal

209 Schirmer test results, and expression of the ocular surface inflammatory markers human leukocyte anti

210 f TBI severity or use of protective eyewear, ocular surface injuries and endothelial cell abnormaliti

211 use or severity level of TBI and presence of ocular surface injuries from blast.

212 Ocular surface injuries were present in 25% (16 of 65) o

213 types to restore the limbal niche following ocular surface injury or disease.

214 Presence of ocular surface injury or endothelial cell abnormalities

215 Eyes with ocular surface injury were more likely to have lower end

216 0 eyes) using an interferometer (LipiView(R) ocular surface interferometer, TearScience Inc, Morrisvi

217 m insufficiency and signs and/or symptoms of ocular surface irritation.

218 The ocular surface is a unique mucosal immune compartment in

219 rophils, eosinophils, and lymphocytes to the ocular surface is due to establishing various chemokine

220 to the mucosal graft when the anatomy of the ocular surface is least altered with best outcomes.

221 When clinical differential diagnosis of ocular surface lesions was broad, UHR OCT images provide

222 ns to help guide diagnosis and management of ocular surface lesions.

223 Aggressive ocular surface lubrication is recommended, including the

224 f office-based MIVS gives us insights on the ocular surface microbial profile and vitreous contaminat

225 ce of goblet cell differentiation for normal ocular surface morphogenesis and homeostasis through reg

226 Notch signaling pathway in regulating normal ocular surface morphogenesis and its role in the pathoge

227 on and activates mucin 5/ac synthesis during ocular surface morphogenesis.

228 nsive eye wipe behaviors when applied to the ocular surface of an awake rat.

229 vides evidence of neutrophil activity on the ocular surface of oGVHD patients.

230 chondroitin sulfate preservative free on the ocular surface of patients with dry eye disease during 6

231 bacteria did not induce inflammation on the ocular surface of rabbit eyes, with and without corneal

232 mon bacterial isolates found on the external ocular surface of the pre-operative cataract patients.

233 When compared with the ocular surface of wild-type mice (OS(Wt)), expression of

234 When transplanted to the ocular surfaces of rabbits, the tissue survived for up t

235 fe treatments for acute inflammations of the ocular surface or adnexa, and showed significantly bette

236 mice (OS(Wt)), expression of dnMaml1 at the ocular surface (OS(dnMaml1)) caused conjunctival epithel

237 We have effectively collected ocular surface (OS) epithelial tissue samples from the L

238 All eyes achieved a stable ocular surface over a mean follow-up of 15 months (range

239 among patients with and without corneal and ocular surface pain at initial and follow-up visits over

240 ltidimensional quantification of corneal and ocular surface pain intensity, and QoL.

241 NaC MG KO mice (5 to 11 months), significant ocular surface pathologies were noted, including corneal

242 Lid and periocular abnormalities, ocular surface pathologies, neuro-ophthalmologic abnorma

243 an approximately 8.5 mV hyperpolarization in ocular surface potential difference.

244 ase of CCL22 could also recruit Tregs to the ocular surface potentially mediating inflammation and sy

245 Ocular surface preparation consisted of topical anesthet

246 Ocular surface preparation for intravitreal injection us

247 Ocular surface protection while achieving disease contro

248 ss, and therapeutic goals (improved comfort, ocular surface protection, or resolution of keratopathy)

249 and without control children, suggests that ocular surface pyogenic granulomas respond to topical ti

250 nted of 4 consecutive children with acquired ocular surface pyogenic granulomas treated at Boston Chi

251 Ocular surface reconstruction (OSR) using tissue-enginee

252 ee corneal epithelial tissue engineering for ocular surface reconstruction.

253 s with an interest in eye development and/or ocular-surface regeneration.

254 In the absence of eye protection, the human ocular surface remains vulnerable to infection with aero

255 optosis and caused a severe pathology of the ocular surface resembling Meibomian gland dysfunction.

256 differential effect of CsA on T cells versus ocular surface resident epithelial cells may contribute

257 e of preformed mediators underlies the acute ocular surface response while the secondary influx of in

258 Ocular surface restoration in partial LSCD is possible w

259 In addition to protecting the ocular surface, scleral lenses improve visual acuity in

260 0.85; 95% CI, -0.33 to 0.62; P = .40) or an ocular surface score (regression coefficient, 1.09; 95%

261 lysis, male sex was associated with a higher ocular surface score, while older age and diabetes were

262 l domains of the OSDI, even though objective ocular surface signs are no worse.

263 ne therapy is effective not only in reducing ocular surface signs in DED patients, but also especiall

264 ents (6%) presented to ophthalmologists with ocular surface signs related to XP, before any formal di

265 reating conjunctival lesions suspected to be ocular surface squamous neoplasia (OSSN) based on the cl

266 To compare the surgical outcomes of ocular surface squamous neoplasia (OSSN) following wide

267 l features are unreliable for distinguishing ocular surface squamous neoplasia (OSSN) from benign con

268 Treatment for ocular surface squamous neoplasia (OSSN) has historicall

269 Ocular surface squamous neoplasia (OSSN) is an aggressiv

270 terferon-alpha 2b (IFNalpha2b) treatment for ocular surface squamous neoplasia (OSSN).

271 Ocular surface squamous neoplasia in HIV-positive indivi

272 Ocular surface squamous neoplasia is uncommonly found to

273 Ocular surface squamous neoplasia specimens were analyze

274 e, allograft OSST can provide true long-term ocular surface stability and successful visual outcomes.

275 Ocular surface stability and visual improvement were the

276 Ocular surface stability was achieved in 72.7% (120/165)

277 ics, symptoms, best-corrected visual acuity, ocular surface stability, adverse events, and additional

278 Ocular surface stability, best-corrected visual acuity (

279 jects, blink rate positively correlated with ocular surface staining and irritation and inversely cor

280 ical signs (tear stability, tear production, ocular surface staining, bulbar and limbal redness, tear

281 evaporation, tear hyperosmolarity, increased ocular surface staining, increased inflammation, symptom

282 lar pressure, lisamine green and fluorescein ocular surface stains.

283 metrics of improvement in dry eye symptoms, ocular-surface status, artificial tear use, contact lens

284 To investigate the long-term outcomes of ocular surface stem cell allograft transplantation (OSST

285 main outcome measures were the frequency of ocular surface symptoms and the correlation between symp

286 ed with ATs or EH lowered the antigen-raised ocular surface temperature to less than the pre-exposure

287 Similar to other proteins placed on the ocular surface, the durability of its effect is limited

288 30 patients with SJS-induced dry keratinized ocular surfaces; the patients underwent various stages o

289 ve strain in vivo, NETs were released at the ocular surface to capture bacteria, limiting their sprea

290 hitecture by use of an automated method; and ocular surface touch sensitivity by use of contact esthe

291 Ocular surface trauma was associated with other ocular i

292 tial, especially in screening for eyelid and ocular surface tumors.

293 to test the tolerability of bacteria on the ocular surface using in vitro and in vivo models.

294 cript explores a novel strategy to reach the ocular surface via receptor-mediated transcytosis across

295 tear film break-up time, Schirmer test, and ocular surface vital staining.

296 reviously, conditional loss of Notch1 on the ocular surface was found to cause inflammation and kerat

297 The kinetics of FODE removal from the ocular surface were analyzed by sampling tears from cont

298 Regular corneal epithelium and a quiet ocular surface were obtained in all patients by a median

299 these studies typically overlook the role of ocular surfaces, which represent both a potential site o

300 icelles results in enhanced contact with the ocular surface while their small size allows better tiss